
Eileen P. Morgan
Examiner (ID: 13601, Phone: (571)272-4488 , Office: P/3723 )
| Most Active Art Unit | 3723 |
| Art Unit(s) | 3616, 3723, 3203 |
| Total Applications | 2918 |
| Issued Applications | 2247 |
| Pending Applications | 80 |
| Abandoned Applications | 595 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19808255
[patent_doc_number] => 12239614
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-04
[patent_title] => Pharmacological prophylactics against stress-induced affective disorders in females
[patent_app_type] => utility
[patent_app_number] => 17/954864
[patent_app_country] => US
[patent_app_date] => 2022-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 44
[patent_figures_cnt] => 75
[patent_no_of_words] => 30106
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17954864
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/954864 | Pharmacological prophylactics against stress-induced affective disorders in females | Sep 27, 2022 | Issued |
Array
(
[id] => 18193284
[patent_doc_number] => 20230046803
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS
[patent_app_type] => utility
[patent_app_number] => 17/953768
[patent_app_country] => US
[patent_app_date] => 2022-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18442
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17953768
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/953768 | COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS | Sep 26, 2022 | Abandoned |
Array
(
[id] => 18166690
[patent_doc_number] => 20230033294
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/944751
[patent_app_country] => US
[patent_app_date] => 2022-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17944751
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/944751 | Succinate prodrug, compositions containing the succinate prodrug and uses thereof | Sep 13, 2022 | Issued |
Array
(
[id] => 18306103
[patent_doc_number] => 20230110003
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT)
[patent_app_type] => utility
[patent_app_number] => 17/941061
[patent_app_country] => US
[patent_app_date] => 2022-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23868
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17941061
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/941061 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Sep 8, 2022 | Abandoned |
Array
(
[id] => 19614904
[patent_doc_number] => 20240400584
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => COMPOUNDS AND METHODS FOR MODULATING SPLICING
[patent_app_type] => utility
[patent_app_number] => 18/688081
[patent_app_country] => US
[patent_app_date] => 2022-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 120769
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18688081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/688081 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Aug 29, 2022 | Pending |
Array
(
[id] => 20192213
[patent_doc_number] => 20250268923
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-28
[patent_title] => APPLICATION OF TETRACYCLINE COMPOUND IN TREATMENT OF TUMOR
[patent_app_type] => utility
[patent_app_number] => 18/686461
[patent_app_country] => US
[patent_app_date] => 2022-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15618
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18686461
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/686461 | APPLICATION OF TETRACYCLINE COMPOUND IN TREATMENT OF TUMOR | Aug 22, 2022 | Pending |
Array
(
[id] => 18107970
[patent_doc_number] => 20230000850
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => COMPOSITION AND METHODS FOR TREATING HERITABLE PULMONARY ARTERY HYPERTENSION ASSOCIATED WITH NONSENSE MUTATIONS
[patent_app_type] => utility
[patent_app_number] => 17/892840
[patent_app_country] => US
[patent_app_date] => 2022-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10616
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 337
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17892840
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/892840 | COMPOSITION AND METHODS FOR TREATING HERITABLE PULMONARY ARTERY HYPERTENSION ASSOCIATED WITH NONSENSE MUTATIONS | Aug 21, 2022 | Abandoned |
Array
(
[id] => 19519804
[patent_doc_number] => 12121502
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-22
[patent_title] => D-serine inhibits neuroinflammation due to a brain injury
[patent_app_type] => utility
[patent_app_number] => 17/890342
[patent_app_country] => US
[patent_app_date] => 2022-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 3051
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17890342
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/890342 | D-serine inhibits neuroinflammation due to a brain injury | Aug 17, 2022 | Issued |
Array
(
[id] => 18056219
[patent_doc_number] => 20220387305
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => COMPOSITION AND METHOD FOR TREATMENT OF DIABETES
[patent_app_type] => utility
[patent_app_number] => 17/890655
[patent_app_country] => US
[patent_app_date] => 2022-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6525
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 170
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17890655
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/890655 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES | Aug 17, 2022 | Pending |
Array
(
[id] => 18034593
[patent_doc_number] => 20220378808
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => FOSPROPOFOL FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/882711
[patent_app_country] => US
[patent_app_date] => 2022-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17882711
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/882711 | Fospropofol formulations | Aug 7, 2022 | Issued |
Array
(
[id] => 18221775
[patent_doc_number] => 20230060769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => COMPOSITION AND METHOD HAVING ENHANCED LSESr TO MAINTAIN AND PROMOTE URINARY AND PROSTATE FUNCTION IN A HUMAN
[patent_app_type] => utility
[patent_app_number] => 17/818011
[patent_app_country] => US
[patent_app_date] => 2022-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18862
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818011
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/818011 | Composition and method having enhanced LSESr to maintain and promote urinary and prostate function in a human | Aug 7, 2022 | Issued |
Array
(
[id] => 19989551
[patent_doc_number] => 20250127773
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-24
[patent_title] => MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE
[patent_app_type] => utility
[patent_app_number] => 18/682162
[patent_app_country] => US
[patent_app_date] => 2022-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18682162
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/682162 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE | Aug 4, 2022 | Pending |
Array
(
[id] => 18466882
[patent_doc_number] => 20230201162
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => TREATMENT FOR PRIMARY BILIARY CHOLANGITIS
[patent_app_type] => utility
[patent_app_number] => 17/880949
[patent_app_country] => US
[patent_app_date] => 2022-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13517
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17880949
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/880949 | Treatment for primary biliary cholangitis | Aug 3, 2022 | Issued |
Array
(
[id] => 19777354
[patent_doc_number] => 12226374
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Compositions comprising quinone and/or quinol and methods of preparations and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/816071
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 24024
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 191
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816071
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/816071 | Compositions comprising quinone and/or quinol and methods of preparations and use thereof | Jul 28, 2022 | Issued |
Array
(
[id] => 18177434
[patent_doc_number] => 20230038163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => AMINO ACID COMPOSITIONS AND METHODS FOR THE TREATMENT OF POST-ACUTE SEQUELAE OF COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/872749
[patent_app_country] => US
[patent_app_date] => 2022-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72131
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17872749
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/872749 | Amino acid compositions and methods for the treatment of post-acute sequelae of COVID-19 | Jul 24, 2022 | Issued |
Array
(
[id] => 20171743
[patent_doc_number] => 12390463
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-19
[patent_title] => Dosage forms and regimens for amino acid compounds
[patent_app_type] => utility
[patent_app_number] => 17/869758
[patent_app_country] => US
[patent_app_date] => 2022-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 62
[patent_figures_cnt] => 33
[patent_no_of_words] => 105293
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 632
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17869758
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/869758 | Dosage forms and regimens for amino acid compounds | Jul 19, 2022 | Issued |
Array
(
[id] => 19674448
[patent_doc_number] => 12186286
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Use of senicapoc for treatment of stroke
[patent_app_type] => utility
[patent_app_number] => 17/813158
[patent_app_country] => US
[patent_app_date] => 2022-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 5574
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813158
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/813158 | Use of senicapoc for treatment of stroke | Jul 17, 2022 | Issued |
Array
(
[id] => 19578720
[patent_doc_number] => 12144801
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-19
[patent_title] => Methods and compositions for treatment of epileptic disorders
[patent_app_type] => utility
[patent_app_number] => 17/863902
[patent_app_country] => US
[patent_app_date] => 2022-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 8
[patent_no_of_words] => 20407
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17863902
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/863902 | Methods and compositions for treatment of epileptic disorders | Jul 12, 2022 | Issued |
Array
(
[id] => 20451803
[patent_doc_number] => 12514846
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
[patent_app_type] => utility
[patent_app_number] => 17/811220
[patent_app_country] => US
[patent_app_date] => 2022-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30214
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 168
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811220
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811220 | Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach | Jul 6, 2022 | Issued |
Array
(
[id] => 19387784
[patent_doc_number] => 20240277654
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => TREATMENT OF SEROTONIN REUPTAKE INHIBITOR WITHDRAWAL SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/571752
[patent_app_country] => US
[patent_app_date] => 2022-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8372
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18571752
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/571752 | TREATMENT OF SEROTONIN REUPTAKE INHIBITOR WITHDRAWAL SYNDROME | Jul 5, 2022 | Pending |